trending Market Intelligence /marketintelligence/en/news-insights/trending/aw1los_dvgr3xjctaofbsw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Heron Therapeutics to raise $156M via public offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Heron Therapeutics to raise $156M via public offering

Heron Therapeutics Inc. priced a public offering of 6 million shares at $26 apiece, hoping to raise $156 million.

Jefferies, Cowen and Evercore ISI are acting as joint book-running managers of the offering, which is expected to close by April 3.

Cantor and JMP Securities are acting as lead managers for the offering.

LifeSci Capital, Lake Street Capital Markets, National Securities Corp., Noble Capital Markets and Northland Capital Markets are each acting as co-managers for the offering.

The underwriters can purchase up to an additional 900,000 shares.

The San Diego-based biotechnology company intends to use the net proceeds for the commercial launch of HTX-011 as a treatment of post-surgery pain in the U.S. once approved.

Heron also plans to use the net proceeds for the continued commercialization of medicines Cinvanti and Sustol, which are used to prevent acute and delayed chemotherapy-induced nausea and vomiting.